Human epidermal growth factor receptor 2 testing in primary breast cancer in the era of standardized testing: a Canadian prospective study.

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Journal of Clinical Oncology

• Publication date

  2014-11-10

• Fields of study

  Medicine

• Identifiers
  DOI 10.1200/JCO.2014.55.6092PMID 25385731
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Assessing the potential cost-effectiveness of retesting IHC0, IHC1+, or FISH-negative early stage breast cancer patients for HER2 status

  2014influential reference
• Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013

  2013cited by this paper
• years versus 1 year of adjuvant trastuzumab for HER 2-positive breast cancer ( HERA ) : an open-label , randomised controlled trial

  2013cited by this paper
• Assessing the potential cost‐effectiveness of retesting IHC0, IHC1+, or FISH‐negative early stage breast cancer patients for HER2 status

  2013cited by this paper
• Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update.

  2013influential reference
• 2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial.

  2013cited by this paper
• Determining sensitivity and specificity of HER2 testing in breast cancer using a tissue micro-array approach

  2012cited by this paper
• Locally recurrent or metastatic breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

  2012cited by this paper
• [Analysis of HER2 status in breast carcinoma using fully automated HER2 staining and fluorescence in-situ hybridization technology].

  2012cited by this paper
• Assessing HER2 amplification in breast cancer: findings from the Australian In Situ Hybridization Program

  2012cited by this paper
• HER2-negative (1+) breast cancer with unfavorable prognostic features: to FISH or not to FISH?

  2012cited by this paper
• Adjuvant trastuzumab in HER2-positive breast cancer.

  2012cited by this paper
• Breast cancer - one term, many entities?

  2011cited by this paper
• Adjuvant trastuzumab in HER2-positive breast cancer.

  2011cited by this paper
• Membrane connectivity estimated by digital image analysis of HER2 immunohistochemistry is concordant with visual scoring and fluorescence in situ hybridization results: algorithm evaluation on breast cancer tissue microarrays

  2011cited by this paper
• Adjuvant Trastuzumab in HER 2-Positive Breast Cancer

  2011cited by this paper
• Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31.

  2011cited by this paper
• HER2-testing in 538 consecutive breast cancer cases using FISH and immunohistochemistry.

  2010cited by this paper
• Locally recurrent or metastatic breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

  2010cited by this paper
• Inter-observer reproducibility of HER2 immunohistochemical assessment and concordance with fluorescent in situ hybridization (FISH): pathologist assessment compared to quantitative image analysis

  2009cited by this paper
• Reply to G. Sauter et al.

  2009cited by this paper
• Computer-assisted assessment of the Human Epidermal Growth Factor Receptor 2 immunohistochemical assay in imaged histologic sections using a membrane isolation algorithm and quantitative analysis of positive controls

  2008cited by this paper
• New cutpoints to identify increased HER2 copy number: analysis of a large, population-based cohort with long-term follow-up

  2008cited by this paper
• Automated quantitative analysis of estrogen receptor expression in breast carcinoma does not differ from expert pathologist scoring: a tissue microarray study of 3,484 cases

  2008influential reference
• Testing for HER2-positive breast cancer: a systematic review and cost-effectiveness analysis

  2007cited by this paper
• Updated recommendations from the Canadian National Consensus Meeting on HER2/neu testing in breast cancer

  2007cited by this paper
• American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer.

  2007cited by this paper
• Histopathologic Characteristics Predicting HER-2/neu Amplification in Breast Cancer

  2007cited by this paper
• Chromogenic in situ hybridisation for the assessment of HER2 status in breast cancer: an international validation ring study

  2007cited by this paper
• Immunohistochemical detection using the new rabbit monoclonal antibody SP1 of estrogen receptor in breast cancer is superior to mouse monoclonal antibody 1D5 in predicting survival.

  2006cited by this paper
• American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer.

  2006cited by this paper
• Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group.

  2005cited by this paper
• Simultaneous detection of HER2/neu gene amplification and protein overexpression in paraffin‐embedded breast cancer

  2005cited by this paper
• Determination of HER2 Gene Amplification by Fluorescence In situ Hybridization and Concordance with the Clinical Trials Immunohistochemical Assay in Women with Metastatic Breast Cancer Evaluated for Treatment with Trastuzumab

  2005cited by this paper
• Histopathologic Characteristics Predicting HER‐2/neu Amplification in Breast Cancer

  2005cited by this paper
• Population-based validation of the prognostic model ADJUVANT! for early breast cancer.

  2005cited by this paper
• Ten-year outcomes in a population-based cohort of node-negative, lymphatic, and vascular invasion-negative early breast cancers without adjuvant systemic therapies.

  2004cited by this paper
• HER2 amplification ratios by fluorescence in situ hybridization and correlation with immunohistochemistry in a cohort of 6556 breast cancer tissues.

  2004influential reference
• HER-2 testing in breast cancer using immunohistochemical analysis and fluorescence in situ hybridization: a single-institution experience of 2,279 cases and comparison of dual-color and single-color scoring.

  2004cited by this paper
• HER-2 testing in breast cancer using parallel tissue-based methods.

  2004cited by this paper
• Comparative multi‐methodological measurement of ERBB2 status in breast cancer

  2004cited by this paper
• Strong HER-2/neu protein overexpression by immunohistochemistry often does not predict oncogene amplification by fluorescence in situ hybridization.

  2003cited by this paper
• NCCN breast cancer clinical practice guidelines in oncology: an update.

  2003cited by this paper
• Impact of polysomy 17 on HER-2/neu immunohistochemistry in breast carcinomas without HER-2/neu gene amplification.

  2003cited by this paper
• Protein overexpression and gene amplification of c-erbB-2 in breast carcinomas: a comparative study of immunohistochemistry and fluorescence in situ hybridization of formalin-fixed, paraffin-embedded tissues.

  2002cited by this paper
• Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

  2001cited by this paper
• Evaluation of the United States Food and Drug Administration-approved scoring and test system of HER-2 protein expression in breast cancer.

  2001cited by this paper
• Laboratory assessment of the status of Her-2/neu protein and oncogene in breast cancer specimens: comparison of immunohistochemistry assay with fluorescence in situ hybridisation assays

  2000cited by this paper
• Relationship between tumor location and relapse in 6,781 women with early invasive breast cancer.

  2000cited by this paper
• neu/erbB-2 amplification identifies a poor-prognosis group of women with node-negative breast cancer. Toronto Breast Cancer Study Group.

  1998cited by this paper
• HER-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas.

  1997cited by this paper
• Compliance with practice guidelines for node-negative breast cancer.

  1997cited by this paper
• Association of C‐erbB‐2 protein over‐expression with high rate of cell proliferation, increased risk of visceral metastasis and poor long‐term survival in breast cancer

  1991cited by this paper
• Survival with breast cancer: the importance of estrogen receptor quantity.

  1989cited by this paper
• Model for breast cancer survival: relative prognostic roles of axillary nodal status, TNM stage, estrogen receptor concentration, and tumor necrosis.

  1988cited by this paper
• Oestrogen receptors, nodes and stage as predictors of post-recurrence survival in 457 breast cancer patients.

  1987cited by this paper
• Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene.

  1987cited by this paper
• T E C H N I C a L a D V a N C E Open Access Clinical Array-based Karyotyping of Breast Cancer with Equivocal Her2 Status Resolves Gene Copy Number and Reveals Chromosome 17 Complexity

  year unknowncited by this paper

• Impact of Ethnic Differences and HER2 Protein Expression on the Age at Breast Cancer Diagnosis: A Mixed Methods Study

  2026cites this paper
• A comparative study of gastric adenocarcinoma HER2 IHC phenotype and mass spectrometry-based quantification

  2023cites this paper
• Assessment of HER2 using the 2018 ASCO/CAP guideline update for invasive breast cancer: a critical look at cases classified as HER2 2+ by immunohistochemistry

  2021cites this paper
• Correlation of Serum HER-2/neu Levels with Clinico-Pathological Variables and Tissue Immunohistochemistry in Breast Carcinoma

  2021cites this paper
• HER2 testing in breast cancers: comparison of assays and interpretation using ASCO/CAP 2013 and 2018 guidelines

  2021cites this paper
• Weakly-Supervised Classification of HER2 Expression in Breast Cancer Haematoxylin and Eosin Stained Slides

  2020cites this paper
• The Impact of Partial Weak Staining in Normal Breast Epithelium on the Reliability of Immunohistochemistry Results in HercepTest-positive Breast Cancer.

  2019cites this paper
• Comparison of Dako HercepTest and Ventana PATHWAY Anti-HER2 (4B5) Tests and Their Correlation With Fluorescent In Situ Hybridization in Breast Carcinoma

  2019cites this paper
• Pilot Study on the Utility of Circulating HER2/Neu Levels in the Serum of Breast Cancer Patients

  2019cites this paper
• THE BOTTOM LINE Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer : American Society of Clinical Oncology / College of American Pathologists Clinical Practice Guideline Focused Update Guideline Questions

  2018cites this paper
• Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update.

  2018cites this paper
• Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update.

  2018cites this paper
• HER2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update Summary.

  2018cites this paper
• Well‐differentiated invasive breast cancers with equivocal HER2 immunohistochemistry: what is the yield of routine reflex in‐situ hybridization testing?

  2017cites this paper
• Comparative Analysis of Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer According to 2007 and 2013 American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations.

  2017cites this paper
• Current HER2 Testing Recommendations and Clinical Relevance as a Predictor of Response to Targeted Therapy.

  2015cites this paper
• High HER2 protein levels correlate with increased survival in breast cancer patients treated with anti‐HER2 therapy

  2015influential citation
• Can We Be Confident of HER2 Testing

  2014cites this paper